Method of Assigning Patients to Treatment Groups in Clinical Study Report
ICH E3 section 9.4.3 calls for the specific method used to assign patients to treatment groups, including relevant allocation, stratification, or blocking features. This report-body method section is distinct from the detailed randomization scheme and codes placed in appendix 16.1.7 and should not imply randomization when the study used another assignment method.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Describe how patients were allocated to treatment groups and identify material stratification, blocking, centralized, site-level, adaptive, or other assignment features that affected allocation.
Key details
Core IssueICH E3 section 9.4.3 calls for the specific method used to assign patients to treatment groups, including relevant allocation, stratification, or blocking features.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This report-body method section is distinct from the detailed randomization scheme and codes placed in appendix 16.1.7 and should not imply randomization when the study used another assignment method.
Further guidance
Content
Describe how patients were allocated to treatment groups and identify material stratification, blocking, centralized, site-level, adaptive, or other assignment features that affected allocation.
Purpose
Describe how patients were allocated to treatment groups and identify material stratification, blocking, centralized, site-level, adaptive, or other assignment features that affected allocation.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 9.2 calls for discussion of the chosen control and study design, including design problems or biases that may matter for interpretation. This guide concerns the rationale and limitations of the control/design choice; the Study Design guide owns the descriptive overview of the study configuration itself.
ICH E3 section 11.4.2.6 calls for efficacy analyses in relevant patient subsets to be presented or discussed when subgroup evidence is important to interpretation. Keep a defined efficacy subset distinct from the primary analysis population and from exploratory subgroup claims that require their own interpretation.
ICH E3 section 9.3.3 identifies Removal of Patients from Therapy or Assessment as a planned study-population subsection of the investigational plan. This subsection states planned removal criteria or procedures; it is not the same as the results-stage disposition of patients or a listing of patients who actually discontinued.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
ICH E3 section 9.5.2 calls for discussion of the appropriateness, reliability, or relevance of measurements used to assess efficacy and safety when explanation is needed. This subsection justifies or qualifies measurement choices; it does not replace the section that defines the variables, methods, and timing of assessments.
ICH E3 section 12.2.1 calls for a brief summary of adverse events within the safety evaluation before more detailed displays and analyses. Keep this section a high-level summary; it is not a substitute for detailed adverse-event displays, patient-level listings, serious-event treatment, or narratives.
